Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Accumulated Expenses (2016)

Cartesian Therapeutics (RNAC) has disclosed Other Accumulated Expenses for 2 consecutive years, with $831000.0 as the latest value for Q2 2016.

  • For Q2 2016, Other Accumulated Expenses changed N/A year-over-year to $831000.0; the TTM value through Jun 2016 reached $831000.0, changed N/A, while the annual FY2015 figure was $223000.0, N/A changed from the prior year.
  • Other Accumulated Expenses hit $831000.0 in Q2 2016 for Cartesian Therapeutics, up from $223000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $831000.0 in Q2 2016 and bottomed at $223000.0 in Q4 2015.